Compare ACRS & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | TRNS |
|---|---|---|
| Founded | 2012 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 799.0M |
| IPO Year | 2015 | 1995 |
| Metric | ACRS | TRNS |
|---|---|---|
| Price | $5.52 | $83.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $10.20 | ★ $116.00 |
| AVG Volume (30 Days) | ★ 2.4M | 70.8K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $1,683,000.00 | ★ $331,877,000.00 |
| Revenue This Year | N/A | $21.75 |
| Revenue Next Year | $4.24 | $7.55 |
| P/E Ratio | ★ N/A | $609.14 |
| Revenue Growth | N/A | ★ 19.20 |
| 52 Week Low | $1.74 | $50.23 |
| 52 Week High | $6.60 | $100.00 |
| Indicator | ACRS | TRNS |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 43.92 |
| Support Level | $4.13 | $67.74 |
| Resistance Level | $5.87 | $86.30 |
| Average True Range (ATR) | 0.33 | 2.89 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 40.93 | 50.55 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.